GlassScriptPhysician profile
David P Cork
NPI 1427369271
$47,516.27
in general payments reported to CMS, 2019-2025
31 companies · $7,267 in 2025
The $7,267 reported for 2025 was more than what 93% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $7,468 · 2021: $5,315 · 2022: $1,282 · 2023: $1,403 · 2024: $459 · 2025: $7,267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,675 · Food and Beverage: $3,382 · Travel and Lodging: $2,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,675.00 |
| Food and Beverage | $3,381.54 |
| Travel and Lodging | $2,072.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $22,447.59 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $15,083.47 | 2019-2025 | General - Brady, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $5,209.06 | 2019-2025 | Aveir, Mitraclip, Cardiomems |
| Medtronic, INC. | $2,527.08 | 2021-2025 | Linq II, Azure Xt Dr Mri Surescan, Micra |
| Amgen INC. | $406.04 | 2019-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.77 | 2019 | |
| Biotronik INC. | $294.80 | 2019-2021 | |
| Esperion Therapeutics, INC. | $228.12 | 2021-2024 | Nexletol |
| Medtronic Vascular, INC. | $153.93 | 2020 | |
| Pfizer INC. | $142.02 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $112.27 | 2019-2025 | Lokelma, Andexxa |
| Novartis Pharmaceuticals Corporation | $98.44 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $85.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $61.53 | 2019 | |
| Irhythm Technologies, INC. | $51.00 | 2019-2024 | Zio Monitor, Zio Xt Patch |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lantheus Medical Imaging, INC. | $50.68 | 2021-2024 | |
| Regeneron Healthcare Solutions, INC. | $35.96 | 2019-2022 | |
| Novo Nordisk INC | $32.66 | 2025 | Ozempic, Rybelsus |
| Heartflow, INC. | $32.53 | 2019 | |
| Kestra Medical Technology Services, INC. | $28.75 | 2023 | Assure Wcd |
| Amarin Pharma, INC. | $20.98 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $15.76 | 2020 | |
| Lundbeck LLC | $15.26 | 2021 | |
| Abbvie INC. | $14.40 | 2025 | |
| Baxter Healthcare | $13.95 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Arbor Pharmaceuticals, INC. | $13.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.64 | 2019 | |
| Tactile Systems Technology INC | $11.19 | 2019 | |
| Travere Therapeutics, INC. | $4.37 | 2020-2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cork listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.